お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は好中球減少症の生物学的製剤治療市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートは好中球減少症の生物学的製剤治療の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界の好中球減少症の生物学的製剤治療市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは好中球減少症の生物学的製剤治療のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に好中球減少症の生物学的製剤治療市場を分類しています。本研究に含まれる主な企業は：Teva Pharmaceutical、Amgen、Sanofi、Mylan(Fulphila)、Kyowa Kirin、Novartis、Spectrum Pharmaceuticals、Pfizer、Baxter International、Partner Therapeutics(Leukine)、BeyondSpring Pharmaceuticals、Cellerant Therapeutics、Enzychem Lifesciences Corporation、Myelo Therapeutics、Generon

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Filgrastim
    Pegfilgrastim
    Lenograstim
    Lipegfilgrastim
    Sargramostim

用途別の市場セグメント：
    Retail Pharmacies
    Hospital Pharmacies
    Online Pharmacies

本レポートの詳細内容
世界の好中球減少症の生物学的製剤治療市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、好中球減少症の生物学的製剤治療タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の好中球減少症の生物学的製剤治療収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の好中球減少症の生物学的製剤治療市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、好中球減少症の生物学的製剤治療市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

好中球減少症の生物学的製剤治療のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：好中球減少症の生物学的製剤治療のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：好中球減少症の生物学的製剤治療の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章好中球減少症の生物学的製剤治療企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：好中球減少症の生物学的製剤治療の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：好中球減少症の生物学的製剤治療の主要企業の概要を提供し、製品の説明と仕様、好中球減少症の生物学的製剤治療の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

 Neutropenia is a clinical condition characterized by a decrease in neutrophil count in the blood, resulting in a higher risk of developing serious infections. A neutrophil is a type of white blood cell, which helps in fighting infections. The major causes of neutropenia include cancer chemotherapy, infections, bone marrow disorders, autoimmune disorders, and the use of specific drugs. 
Market Analysis and Insights: Global Neutropenia Biologic Drug Treatment Market
The global Neutropenia Biologic Drug Treatment market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Neutropenia Biologic Drug Treatment market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Neutropenia Biologic Drug Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Neutropenia Biologic Drug Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Neutropenia Biologic Drug Treatment revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Neutropenia Biologic Drug Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Neutropenia Biologic Drug Treatment revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Teva Pharmaceutical, Amgen, Sanofi, Mylan(Fulphila), Kyowa Kirin, Novartis, Spectrum Pharmaceuticals, Pfizer and Baxter International, etc.

Market Segmentation
By Company
    Teva Pharmaceutical
    Amgen
    Sanofi
    Mylan(Fulphila)
    Kyowa Kirin
    Novartis
    Spectrum Pharmaceuticals
    Pfizer
    Baxter International
    Partner Therapeutics(Leukine)
    BeyondSpring Pharmaceuticals
    Cellerant Therapeutics
    Enzychem Lifesciences Corporation
    Myelo Therapeutics
    Generon

Segment by Type
    By Drug Type
        Filgrastim
        Pegfilgrastim
        Lenograstim
        Lipegfilgrastim
        Sargramostim
    By Treatment Type
        Antibiotic Drugs
        Granulocyte-Colony-Stimulating Factor (G-CSF)
        Antifungal Drugs
        Others

Segment by Application
    Retail Pharmacies
    Hospital Pharmacies
    Online Pharmacies

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Neutropenia Biologic Drug Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neutropenia Biologic Drug Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neutropenia Biologic Drug Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Filgrastim
    Table 3. Key Players of Pegfilgrastim
    Table 4. Key Players of Lenograstim
    Table 5. Key Players of Lipegfilgrastim
    Table 6. Key Players of Sargramostim
    Table 7. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 8. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 9. Global Neutropenia Biologic Drug Treatment Market Size by Region (2019-2024) & (US$ Million)
    Table 10. Global Neutropenia Biologic Drug Treatment Market Share by Region (2019-2024)
    Table 11. Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 12. Global Neutropenia Biologic Drug Treatment Market Share by Region (2025-2030)
    Table 13. Neutropenia Biologic Drug Treatment Market Trends
    Table 14. Neutropenia Biologic Drug Treatment Market Drivers
    Table 15. Neutropenia Biologic Drug Treatment Market Challenges
    Table 16. Neutropenia Biologic Drug Treatment Market Restraints
    Table 17. Global Neutropenia Biologic Drug Treatment Revenue by Players (2019-2024) & (US$ Million)
    Table 18. Global Neutropenia Biologic Drug Treatment Revenue Share by Players (2019-2024)
    Table 19. Global Top Neutropenia Biologic Drug Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neutropenia Biologic Drug Treatment as of 2023)
    Table 20. Global Neutropenia Biologic Drug Treatment Industry Ranking 2022 VS 2023 VS 2024
    Table 21. Global 5 Largest Players Market Share by Neutropenia Biologic Drug Treatment Revenue (CR5 and HHI) & (2019-2024)
    Table 22. Global Key Players of Neutropenia Biologic Drug Treatment, Headquarters and Area Served
    Table 23. Global Key Players of Neutropenia Biologic Drug Treatment, Product and Application
    Table 24. Global Key Players of Neutropenia Biologic Drug Treatment, Product and Application
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Neutropenia Biologic Drug Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 27. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2019-2024)
    Table 28. Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 29. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2025-2030)
    Table 30. Global Neutropenia Biologic Drug Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 31. Global Neutropenia Biologic Drug Treatment Revenue Share by Application (2019-2024)
    Table 32. Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 33. Global Neutropenia Biologic Drug Treatment Revenue Share by Application (2025-2030)
    Table 34. North America Neutropenia Biologic Drug Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 35. North America Neutropenia Biologic Drug Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 36. North America Neutropenia Biologic Drug Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 37. North America Neutropenia Biologic Drug Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 38. North America Neutropenia Biologic Drug Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 39. North America Neutropenia Biologic Drug Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 40. North America Neutropenia Biologic Drug Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 41. Europe Neutropenia Biologic Drug Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 42. Europe Neutropenia Biologic Drug Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 43. Europe Neutropenia Biologic Drug Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 44. Europe Neutropenia Biologic Drug Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 45. Europe Neutropenia Biologic Drug Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 46. Europe Neutropenia Biologic Drug Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 47. Europe Neutropenia Biologic Drug Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 48. China Neutropenia Biologic Drug Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 49. China Neutropenia Biologic Drug Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 50. China Neutropenia Biologic Drug Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 51. China Neutropenia Biologic Drug Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 52. Asia Neutropenia Biologic Drug Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 53. Asia Neutropenia Biologic Drug Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 54. Asia Neutropenia Biologic Drug Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 55. Asia Neutropenia Biologic Drug Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 56. Asia Neutropenia Biologic Drug Treatment Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 57. Asia Neutropenia Biologic Drug Treatment Market Size by Region (2019-2024) & (US$ Million)
    Table 58. Asia Neutropenia Biologic Drug Treatment Market Size by Region (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Neutropenia Biologic Drug Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Neutropenia Biologic Drug Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Neutropenia Biologic Drug Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Neutropenia Biologic Drug Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Neutropenia Biologic Drug Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 64. Middle East, Africa, and Latin America Neutropenia Biologic Drug Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 65. Middle East, Africa, and Latin America Neutropenia Biologic Drug Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 66. Teva Pharmaceutical Company Details
    Table 67. Teva Pharmaceutical Business Overview
    Table 68. Teva Pharmaceutical Neutropenia Biologic Drug Treatment Product
    Table 69. Teva Pharmaceutical Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 70. Teva Pharmaceutical Recent Developments
    Table 71. Amgen Company Details
    Table 72. Amgen Business Overview
    Table 73. Amgen Neutropenia Biologic Drug Treatment Product
    Table 74. Amgen Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 75. Amgen Recent Developments
    Table 76. Sanofi Company Details
    Table 77. Sanofi Business Overview
    Table 78. Sanofi Neutropenia Biologic Drug Treatment Product
    Table 79. Sanofi Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 80. Sanofi Recent Developments
    Table 81. Mylan(Fulphila) Company Details
    Table 82. Mylan(Fulphila) Business Overview
    Table 83. Mylan(Fulphila) Neutropenia Biologic Drug Treatment Product
    Table 84. Mylan(Fulphila) Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 85. Mylan(Fulphila) Recent Developments
    Table 86. Kyowa Kirin Company Details
    Table 87. Kyowa Kirin Business Overview
    Table 88. Kyowa Kirin Neutropenia Biologic Drug Treatment Product
    Table 89. Kyowa Kirin Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 90. Kyowa Kirin Recent Developments
    Table 91. Novartis Company Details
    Table 92. Novartis Business Overview
    Table 93. Novartis Neutropenia Biologic Drug Treatment Product
    Table 94. Novartis Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 95. Novartis Recent Developments
    Table 96. Spectrum Pharmaceuticals Company Details
    Table 97. Spectrum Pharmaceuticals Business Overview
    Table 98. Spectrum Pharmaceuticals Neutropenia Biologic Drug Treatment Product
    Table 99. Spectrum Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 100. Spectrum Pharmaceuticals Recent Developments
    Table 101. Pfizer Company Details
    Table 102. Pfizer Business Overview
    Table 103. Pfizer Neutropenia Biologic Drug Treatment Product
    Table 104. Pfizer Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 105. Pfizer Recent Developments
    Table 106. Baxter International Company Details
    Table 107. Baxter International Business Overview
    Table 108. Baxter International Neutropenia Biologic Drug Treatment Product
    Table 109. Baxter International Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 110. Baxter International Recent Developments
    Table 111. Partner Therapeutics(Leukine) Company Details
    Table 112. Partner Therapeutics(Leukine) Business Overview
    Table 113. Partner Therapeutics(Leukine) Neutropenia Biologic Drug Treatment Product
    Table 114. Partner Therapeutics(Leukine) Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 115. Partner Therapeutics(Leukine) Recent Developments
    Table 116. BeyondSpring Pharmaceuticals Company Details
    Table 117. BeyondSpring Pharmaceuticals Business Overview
    Table 118. BeyondSpring Pharmaceuticals Neutropenia Biologic Drug Treatment Product
    Table 119. BeyondSpring Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 120. BeyondSpring Pharmaceuticals Recent Developments
    Table 121. Cellerant Therapeutics Company Details
    Table 122. Cellerant Therapeutics Business Overview
    Table 123. Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product
    Table 124. Cellerant Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 125. Cellerant Therapeutics Recent Developments
    Table 126. Enzychem Lifesciences Corporation Company Details
    Table 127. Enzychem Lifesciences Corporation Business Overview
    Table 128. Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product
    Table 129. Enzychem Lifesciences Corporation Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 130. Enzychem Lifesciences Corporation Recent Developments
    Table 131. Myelo Therapeutics Company Details
    Table 132. Myelo Therapeutics Business Overview
    Table 133. Myelo Therapeutics Neutropenia Biologic Drug Treatment Product
    Table 134. Myelo Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 135. Myelo Therapeutics Recent Developments
    Table 136. Generon Company Details
    Table 137. Generon Business Overview
    Table 138. Generon Neutropenia Biologic Drug Treatment Product
    Table 139. Generon Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)
    Table 140. Generon Recent Developments
    Table 141. Research Programs/Design for This Report
    Table 142. Key Data Information from Secondary Sources
    Table 143. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Neutropenia Biologic Drug Treatment Market Share by Type: 2023 VS 2030
    Figure 3. Filgrastim Features
    Figure 4. Pegfilgrastim Features
    Figure 5. Lenograstim Features
    Figure 6. Lipegfilgrastim Features
    Figure 7. Sargramostim Features
    Figure 8. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 9. Global Neutropenia Biologic Drug Treatment Market Share by Application: 2023 VS 2030
    Figure 10. Retail Pharmacies Case Studies
    Figure 11. Hospital Pharmacies Case Studies
    Figure 12. Online Pharmacies Case Studies
    Figure 13. Neutropenia Biologic Drug Treatment Report Years Considered
    Figure 14. Global Neutropenia Biologic Drug Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 15. Global Neutropenia Biologic Drug Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 16. Global Neutropenia Biologic Drug Treatment Market Share by Region: 2023 VS 2030
    Figure 17. Global Neutropenia Biologic Drug Treatment Market Share by Players in 2023
    Figure 18. Global Top Neutropenia Biologic Drug Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neutropenia Biologic Drug Treatment as of 2023)
    Figure 19. The Top 10 and 5 Players Market Share by Neutropenia Biologic Drug Treatment Revenue in 2023
    Figure 20. North America Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. North America Neutropenia Biologic Drug Treatment Market Share by Type (2019-2030)
    Figure 22. North America Neutropenia Biologic Drug Treatment Market Share by Application (2019-2030)
    Figure 23. North America Neutropenia Biologic Drug Treatment Market Share by Country (2019-2030)
    Figure 24. United States Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Canada Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Europe Neutropenia Biologic Drug Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 27. Europe Neutropenia Biologic Drug Treatment Market Share by Type (2019-2030)
    Figure 28. Europe Neutropenia Biologic Drug Treatment Market Share by Application (2019-2030)
    Figure 29. Europe Neutropenia Biologic Drug Treatment Market Share by Country (2019-2030)
    Figure 30. Germany Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. France Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. U.K. Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Italy Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Russia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Nordic Countries Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. China Neutropenia Biologic Drug Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 37. China Neutropenia Biologic Drug Treatment Market Share by Type (2019-2030)
    Figure 38. China Neutropenia Biologic Drug Treatment Market Share by Application (2019-2030)
    Figure 39. Asia Neutropenia Biologic Drug Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 40. Asia Neutropenia Biologic Drug Treatment Market Share by Type (2019-2030)
    Figure 41. Asia Neutropenia Biologic Drug Treatment Market Share by Application (2019-2030)
    Figure 42. Asia Neutropenia Biologic Drug Treatment Market Share by Region (2019-2030)
    Figure 43. Japan Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. South Korea Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. China Taiwan Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. India Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Australia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. Middle East, Africa, and Latin America Neutropenia Biologic Drug Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 50. Middle East, Africa, and Latin America Neutropenia Biologic Drug Treatment Market Share by Type (2019-2030)
    Figure 51. Middle East, Africa, and Latin America Neutropenia Biologic Drug Treatment Market Share by Application (2019-2030)
    Figure 52. Middle East, Africa, and Latin America Neutropenia Biologic Drug Treatment Market Share by Country (2019-2030)
    Figure 53. Brazil Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Mexico Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Turkey Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Saudi Arabia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Israel Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. GCC Countries Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. Teva Pharmaceutical Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 60. Amgen Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 61. Sanofi Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 62. Mylan(Fulphila) Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 63. Kyowa Kirin Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 64. Novartis Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 65. Spectrum Pharmaceuticals Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 66. Pfizer Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 67. Baxter International Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 68. Partner Therapeutics(Leukine) Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 69. BeyondSpring Pharmaceuticals Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 70. Cellerant Therapeutics Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 71. Enzychem Lifesciences Corporation Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 72. Myelo Therapeutics Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 73. Generon Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)
    Figure 74. Bottom-up and Top-down Approaches for This Report
    Figure 75. Data Triangulation
    Figure 76. Key Executives Interviewed